Clinical Trials Logo

Clinical Trial Summary

This investigation examines the most important cardiovascular risk factors (e.g., metabolic parameters, body composition) and their changes in coeliac disease. The series of studies allow to assess body composition and cardiovascular risk-related metabolic parameters of newly diagnosed and treated coeliac patients in their complexity and to test if they change during therapy. The interventional part of the investigation aims to answer the question if a dietary intervention mitigates the unfavorable effects of unbalanced diet.


Clinical Trial Description

The global prevalence of coeliac disease (CD) is increasing, which contributes to the disease's significant public health care burden. Body composition and metabolic parameters of coeliac patients differ from the healthy population. Patients with non-classical CD are not necessarily lean; they usually have normal body weight but can be even overweight or obese. In coeliac patients, bodyweight tends to elevate, whereas the body composition changes unfavourably during a gluten-free diet (GFD). A reason for gaining weight is the improvement of malabsorption but an important contributor is the nutrient composition of the GFD, which generally has a high calorie density with high carbohydrate and fat content while being low in fibre. While terminating or mitigating the inflammatory process - if done without adequate dietary control - a GFD can readily lead to weight gain and unfavourably metabolic consequences (e.g., dyslipidemia, fatty liver disease, insulin resistance). The result can be an increase in cardiovascular risk in CD patients with a normal or high body weight at diagnosis. However, limited information is available on the cardiovascular (CV) risk in coeliac disease, and the data are controversial. This study examines the body composition and cardiovascular risk-related metabolic parameters at the diagnosis and on a gluten-free diet in a Hungarian cohort of CD patients. The randomised controlled trial (RCT) investigates the effect of structured, repeated, group-based dietary education on the examined metabolic parameters and body composition. This study aims to draw attention to a new aspect of the management of CD patients: from a metabolic and cardiovascular point of view. Findings will help to identify which parameters are beneficial to optimize and re-assess during follow-up in CD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05530070
Study type Interventional
Source University of Pecs
Contact Judit Bajor, MD, PhD
Phone +36 72 536 000
Email bajor.judit@pte.hu
Status Recruiting
Phase N/A
Start date September 1, 2022
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT04604795 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole Phase 1
Completed NCT02965209 - European Novel Motorized Spiral Endoscopy Trial N/A
Completed NCT03543540 - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Phase 1
Completed NCT03644602 - Low FODMAPs Diet in Gastrointestinal Disorders N/A
Completed NCT02675283 - Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting N/A
Completed NCT02551289 - MAgnetic Resonance Imaging in COeliac Disease
Active, not recruiting NCT02442219 - A Blood Based Diagnostic Test for Coeliac Disease
Recruiting NCT05786183 - Rapid Technique for the Detection of Intestinal Anti-transglutaminase Antibodies
Recruiting NCT06001177 - A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease Phase 2
Completed NCT00879749 - Safety Study of Nexvax2 in Subjects With Coeliac Disease Phase 1